Hematopoietic stem cell transplantation for Langerhans cell histiocytosis: clinical findings and long-term outcomes

References

• Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med. 2018;379:856–868.
   PubMed Web of Science ®Google Scholar
• Morimoto A, Oh Y, Shioda Y, et al. Recent advances in Langerhans cell histiocytosis. Pediatr Int. 2014;56:451–461.
   PubMed Web of Science ®Google Scholar
• Gadner H, Grois N, Pötschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008;111:2556–2562.
   PubMed Web of Science ®Google Scholar
• Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121:5006–5014.
   PubMed Web of Science ®Google Scholar
• Morimoto A, Ikushima S, Kinugawa N, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans cell histiocytosis study group-96 protocol study. Cancer. 2006;107:613–619.
   PubMed Web of Science ®Google Scholar
• Morimoto A, Shioda Y, Imamura T, et al. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans cell histiocytosis study group-02 protocol study. Int J Hematol. 2016;104:99–109.
   PubMed Web of Science ®Google Scholar
• Minkov M, Steiner M, Pötschger U, et al. Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry. J Pediatr. 2008;153:700–705.
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Morimoto A, Shioda Y, et al. Central diabetes insipidus in pediatric patients with Langerhans cell histiocytosis: results from the JLSG-96/02 studies.Pediatr. Blood Cancer. 2019;66:e27454.
   PubMedGoogle Scholar
• Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-mutant erdheim-chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, Phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4:384–388.
   PubMed Web of Science ®Google Scholar
• Donadieu J, Larabi IA, Tardieu M, et al. Vemurafenib for refractory multisystem langerhans cell histiocytosis in children: an international observational study. J Clin Oncol. 2019;37:2857–2865.
   PubMed Web of Science ®Google Scholar
• Ringden O, Ahstrom L, Lonnqvist B, et al. Allogeneic bone marrow transplantation in a patient with chemotherapy-resistant progressive histiocytosis X. N Engl J Med. 1987;316:733–735.
   PubMed Web of Science ®Google Scholar
• Kinugawa N, Imashuku S, Hirota Y, et al. Hematopoietic stem cell transplantation (HSCT) for Langerhans cell histiocytosis (LCH) in Japan. Bone Marrow Transplant. 1999;24:935–938.
   PubMed Web of Science ®Google Scholar
• Veys PA, Nanduri V, Baker KS, et al. Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. Br J Haematol. 2015;169:711–718.
   PubMed Web of Science ®Google Scholar
• Kudo K, Maeda M, Suzuki N, et al. Nationwide retrospective review of hematopoietic stem cell transplantation in children with refractory Langerhans cell histiocytosis. Int J Hematol. 2020;111:137–148.
   PubMed Web of Science ®Google Scholar
• Stoll M, Freund M, Schmid H, et al. Allogeneic bone marrow transplantation for Langerhans’ cell histiocytosis. Cancer. 1990;66:284–288.
   PubMed Web of Science ®Google Scholar
• Greinix HT, Storb R, Sanders JE, et al. Marrow transplantation for treatment of multisystem progressive Langerhans cell histiocytosis. Bone Marrow Transplant. 1992;10:39–44.
   PubMed Web of Science ®Google Scholar
• Conter V, Reciputo A, Arrigo C, et al. Bone marrow transplantation for refractory Langerhans’ cell histiocytosis. Haematologica. 1996;81:468–471.
   PubMed Web of Science ®Google Scholar
• Frost JD, Wiersma SR. Progressive Langerhans cell histiocytosis in an infant with Klinefelter syndrome successfully treated with allogeneic bone marrow transplantation. J Pediatr Hematol Oncol. 1996;18:396–400.
   PubMed Web of Science ®Google Scholar
• Nagarajan R, Neglia J, Ramsay N, et al. Successful treatment of refractory Langerhans cell histiocytosis with unrelated cord blood transplantation. J Pediatr Hematol Oncol. 2001;23:629–632.
   PubMed Web of Science ®Google Scholar
• Suminoe A, Matsuzaki A, Hattori H, et al. Unrelated cord blood transplantation for an infant with chemotherapy-resistant progressive Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2001;23:633–636.
   PubMed Web of Science ®Google Scholar
• Hale GA, Bowman LC, Woodard JP, et al. Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimen. Bone Marrow Transplant. 2003;31:981–986.
   PubMedGoogle Scholar
• Meyer-Wentrup F, Foell J, Wawer A, et al. Unrelated cord blood transplantation in an infant with severe multisystem Langerhans cell histiocytosis: clinical outcome, engraftment and culture of monocyte-derived dendritic cells. Bone Marrow Transplant. 2004;33:875–876.
   PubMed Web of Science ®Google Scholar
• Ingram W, Desai SR, Gibbs JS, et al. Reduced-intensity conditioned allogeneic haematopoietic transplantation in an adult with Langerhans’ cell histiocytosis and thrombocytopenia with absent radii. Bone Marrow Transplant. 2006;37:713–715.
   PubMedGoogle Scholar
• Ichikawa K, Nomura S, Ishii K, et al. Autologous stem cell transplantation for refractory Langerhans’ cell histiocytosis. Bone Marrow Transplant. 2007;40:807–808.
   PubMed Web of Science ®Google Scholar
• Steiner M, Matthes-Martin S, Attarbaschi A, et al. Importance of allogeneic T-cells for disease control after stem cell transplantation for high-risk Langerhans cell histiocytosis. Haematologica. 2007;92:e3–4.
   PubMedGoogle Scholar
• Chen RL, Wu PL, Hsu YH, et al. Evans syndrome after s transplantation for disseminated Langerhans cell histiocytosis in a child. J Pediatr Hematol Oncol. 2007;29:348–350.
   PubMed Web of Science ®Google Scholar
• Lai CC, Huang WC, Cheng SN. Successful treatment of refractory Langerhans cell histiocytosis by allogeneic peripheral blood stem cell transplantation. Pediatr Transplant. 2008;12:99–104.
   PubMed Web of Science ®Google Scholar
• Cooper N, Rao K, Goulden N, et al. The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis. Bone Marrow Transplant. 2008;42(Suppl 2):S47–50.
   PubMedGoogle Scholar
• Kesik V, Citak C, Kismet E, et al. Hematopoietic stem cell transplantation in Langerhans cell histiocytosis: case report and review of the literature. Pediatr Transplant. 2009;13:371–374.
   PubMed Web of Science ®Google Scholar
• Hatakeyama N, Hori T, Yamamoto M, et al. Successful treatment of refractory Langerhans cell histiocytosis with pulmonary aspergillosis by reduced-intensity conditioning cord blood transplantation. Pediatr Transplant. 2010;14:E4–10.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Ito Y, Shimada A, et al. Long-term parvovirus B19 infections with genetic drift after cord blood transplantation complicated by persistent CD4+ lymphocytopenia. J Pediatr Hematol Oncol. 2014;36:e65–68.
   PubMed Web of Science ®Google Scholar
• Jun Y, Quan QM, Bin W, et al. Haploidentical parental hematopoietic stem cell transplantation in pediatric refractory Langerhans cell histiocytosis. Pediatr Transplant. 2014;18:E124–129.
   PubMed Web of Science ®Google Scholar
• Gabalec F, Šimkovič M, Zavřelová A, et al. Treatment of multifocal multisystem BRAF positive langerhans cell histiocytosis with cladribine, surgery and allogenic stem cell transplantation. Acta Medica (Hradec Kralove). 2017;60:152–156.
   PubMedGoogle Scholar
• Washio K, Muraoka M, Kanamitsu K, et al. A case of refractory langerhans cell histiocytosis complicated with hemophagocytic lymphohistiocytosis rescued by cord blood transplantation with reduced-intensity conditioning. Acta Med Okayama. 2017;71:249–254.
   PubMed Web of Science ®Google Scholar
• Pan Y, Xi R, Wang C, et al. Autologous hematopoietic stem cell transplantation for efficient treatment of multisystem, high-risk, BRAF V600E-negative Langerhans cell histiocytosis. J Int Med Res. 2019;47:4522–4529.
   PubMed Web of Science ®Google Scholar
• Akkari V, Donadieu J, Piguet C, et al. Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: experience of the French Langerhans Cell Study Group. Bone Marrow Transplant. 2003;31:1097–1103.
   PubMedGoogle Scholar
• Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment- resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant. 2005;36:215–225.
   PubMed Web of Science ®Google Scholar
• Kudo K, Ohga S, Morimoto A, et al. Improved outcome of refractory Langerhans cell histiocytosis in children with hematopoietic stem cell transplantation in Japan. Bone Marrow Transplant. 2010;45:901–906.
   PubMed Web of Science ®Google Scholar
• Lau L, Krafchik B, Trebo MM, et al. Cutaneous Langerhans cell histiocytosis in children under one year. Pediatr Blood Cancer. 2006;46:66–71.
   PubMed Web of Science ®Google Scholar
• Haupt R, Minkov M, Astigarraga I, et al. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013;60:175–184.
   PubMed Web of Science ®Google Scholar
• Imashuku S. Langerhans cell histiocytosis and hemophagocytic syndrome in Japan; epidemiological studies. Int J Pediatr Hematol Oncol. 1994;1:241–246.
   Google Scholar
• Titgemeyer C, Grois N, Minkov M, et al. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol. 2001;37:108–114.
   PubMedGoogle Scholar
• Morimoto A, Ishida Y, Suzuki N, et al. Nationwide survey of single-system single site Langerhans cell histiocytosis in Japan. Pediatr Blood Cancer. 2010;54:98–102.
   PubMed Web of Science ®Google Scholar
• Morimoto A, Kobayashi R, Maeda M, et al. Impact of reactivation on the sequelae of multisystem Langerhans cell histiocytosis patients. Pediatr Blood Cancer. 2008;50:931–932.
   PubMed Web of Science ®Google Scholar
• Shioda Y, Adachi S, Imashuku S, et al. Analysis of 43 cases of Langerhans cell histiocytosis (LCH)-induced central diabetes insipidus registered in the JLSG-96 and JLSG-02 studies in Japan. Int J Hematol. 2011;94:545–551.
   PubMed Web of Science ®Google Scholar
• Grois N, Pötschger U, Prosch H, et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer. 2006;46:228–233.
   PubMed Web of Science ®Google Scholar
• Wnorowski M, Prosch H, Prayer D, et al. Pattern and course of neurodegeneration in Langerhans cell histiocytosis. J Pediatr. 2008;153:127–132.
   PubMed Web of Science ®Google Scholar
• Héritier S, Emile JF, Barkaoui MA, et al. BRAF mutation correlates with high-risk langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol. 2016;34:3023–3030.
   PubMed Web of Science ®Google Scholar
• Héritier S, Barkaoui MA, Miron J, et al. Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study. Br J Haematol. 2018;183:608–617.
   PubMed Web of Science ®Google Scholar
• Aricò M, Girschikofsky M, Généreau T, et al. Langerhans cell histiocytosis in adults. Report from the International registry of the histiocyte society. Eur J Cancer. 2003;39:2341–2348.
   PubMed Web of Science ®Google Scholar
• Girschikofsky M, Arico M, Castillo D, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis. 2013;8:72.
   PubMed Web of Science ®Google Scholar
• Imashuku S, Kudo N, Kaneda S, et al. Treatment of patients with hypothalamic-pituitary lesions as adult-onset Langerhans cell histiocytosis. Int J Hematol. 2011;94:556–560.
   PubMed Web of Science ®Google Scholar
• Oh Y, Hayase T, Ito T, et al. Cladribine-related myelodysplastic syndrome in Langerhans cell histiocytosis. Pediatr Int. 2019;61:419–421.
   PubMed Web of Science ®Google Scholar
• Donadieu J, Bernard F, van Noesel M, et al. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. 2015;126:1415–1423.
   PubMed Web of Science ®Google Scholar
• Simko SJ, Tran HD, Jones J, et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer. 2014;61:479–487.
   PubMed Web of Science ®Google Scholar
• Rosso DA, Amaral D, Latella A, et al. Reduced doses of cladribine and cytarabine regimen was effective and well tolerated in patients with refractory-risk multisystem Langerhans cell histiocytosis. Br J Haematol. 2016;172:287–290.
   PubMed Web of Science ®Google Scholar
• Tazi A, Lorillon G, Haroche J, et al. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study. Orphanet J Rare Dis. 2017;12:95.
   PubMed Web of Science ®Google Scholar
• Cantu MA, Lupo PJ, Bilgi M, et al. Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. PLoS One. 2012;7:e43257.
   PubMed Web of Science ®Google Scholar
• Saven A, Burian C. Cladribine activity in adult langerhans‐cell histiocytosis. Blood. 1999;93:4125–4130.
   PubMed Web of Science ®Google Scholar
• Morimoto A, Shimazaki C, Takahashi S, et al. Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the Special C regimen formulated by the Japan LCH Study Group. Int J Hematol. 2013;97:103–108.
   PubMed Web of Science ®Google Scholar
• Zinn DJ, Grimes AB, Lin H, et al. Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood. 2016;128:2462–2465.
   PubMed Web of Science ®Google Scholar
• Duan MH, Han X, Li J, et al. Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first‐line treatment for adult Langerhans cell histiocytosis: a single‐center retrospective study. Leuk Res. 2016;42:43–46.
   PubMed Web of Science ®Google Scholar
• Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet. 1997;32:120–131.
   PubMed Web of Science ®Google Scholar
• Berres ML, Lim KP, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211:669–683.
   PubMed Web of Science ®Google Scholar
• Henden AS, Hill GR. Cytokines in Graft-versus-Host Disease. J Immunol. 2015;194:4604–4612.
   PubMed Web of Science ®Google Scholar
• Morimoto A, Oh Y, Nakamura S, et al. Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis. Cytokine. 2017;97:73–79.
   PubMed Web of Science ®Google Scholar
• Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–650.
   PubMed Web of Science ®Google Scholar
• Jorge AS, Suárez-Lledó M, Pereira A, et al. Single antigen-mismatched unrelated hematopoietic stem cell transplantation using high-dose post-transplantation cyclophosphamide is a suitable alternative for patients lacking HLA-matched donors. Biol Blood Marrow Transplant. 2018;24:1196–1202.
   PubMed Web of Science ®Google Scholar
• Toubai T, Mathewson ND, Magenau J, et al. Danger signals and graft-versus-host disease: current understanding and future perspectives. Front Immunol. 2016;7:539.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–1633.
   PubMed Web of Science ®Google Scholar
• Ringdén O, Lönnqvist B, Holst M. 12-year follow-up of allogeneic bone-marrow transplant for Langerhans’ cell histiocytosis. Lancet. 1997;349:476.
   PubMed Web of Science ®Google Scholar
• Jordan MB, McClain KL, Yan X, et al. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005;44:251–254.
   PubMed Web of Science ®Google Scholar
• Kieran MW, Geoerger B, Dunkel IJ, et al. A Phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory BRAF V600 mutation-positive solid tumors. Clin Cancer Res. 2019;25:7294–7302.
   PubMed Web of Science ®Google Scholar
• Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019;567:521–524.
   PubMed Web of Science ®Google Scholar
• Héritier S, Hélias-Rodzewicz Z, Lapillonne H, et al. Circulating cell-free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis. Br J Haematol. 2017;178:457–467.
   PubMed Web of Science ®Google Scholar
• Schwentner R, Kolenová A, Jug G, et al. Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis. Pediatr Res. 2019;85:856–864.
   PubMed Web of Science ®Google Scholar
• Eckstein OS, Visser J, Rodriguez-Galindo C, et al. Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. Blood. 2019;133:1691–1694.
   PubMed Web of Science ®Google Scholar
• Rea D, Cayuela JM. Treatment-free remission in patients with chronic myeloid leukemia. Int J Hematol. 2018;108:355–364.
   PubMed Web of Science ®Google Scholar